Eliem Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Eliem Therapeutics's estimated annual revenue is currently $4.8M per year.
- Eliem Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Eliem Therapeutics has 31 Employees.
- Eliem Therapeutics grew their employee count by -37% last year.
Eliem Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
Eliem Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Eliem Therapeutics?
Eliem Therapeutics is a clinical-stage company developing medicines for patients with neurologic diseases. Our pipeline has two clinical stage compounds in conditions focused on pain, depression and epilepsy. The company continues to grow its preclinical pipeline in neurology. Eliem has funding from leading healthcare investors RA Capital, Access Biotechnology, and Bridge Valley Ventures. The company has locations in the Greater Seattle area of WA and Cambridge, UK.
keywords:N/A
N/A
Total Funding
31
Number of Employees
$4.8M
Revenue (est)
-37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Eliem Therapeutics News
SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage...
About Eliem Therapeutics, Inc. Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for...
Other Companies in Redmond
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 31 | 82% | N/A |
#2 | $8M | 31 | -11% | N/A |
#3 | $6.2M | 31 | N/A | N/A |
#4 | $6.7M | 31 | -3% | N/A |
#5 | $6.2M | 31 | 7% | N/A |